What potential cost savings were identified for chronic heart failure patients with preserved ejection fraction?
The committee noted that there could be potential cost savings from a reduced number of all cause hospitalisations for those treated with MRAs; however, as mentioned above, the clinical evidence for this outcome is uncertain. The committee also noted the greater number of acute kidney injury (AKI) events occurring in those treated with MRAs and agreed that the high cost of AKI would likely outweigh any potential cost savings from reduced hospitalisation.